Biosimilar Trastuzumab in Clinical Trials: Differences or Not? | Citedby Results | Breast Care | Karger Publishers

Skip to Main Content

Skip Nav Destination

Biosimilar Trastuzumab in Clinical Trials: Differences or Not?

Breast Care (2019) 14 (1): 17–22.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Safety profile of trastuzumab originator vs biosimilars: a systematic review and meta-analysis of randomized clinical trials

Andrea Oliva
Cristina Scavone
Consiglia Riccardi
Francesca Futura Bernardi
Francesco Salvo
Annamaria Mascolo

Clinical and Translational Oncology (2024) 27 (4): 1826.

A Double-blind Randomized Comparative Phase I Study to Assess Biosimilarity and Immunogenicity of "Trastuzumab" (LLC "Mabscale", Russia) and Herceptin® (F. Hoffmann-La Roche Ltd., Switzerland) in Healthy Volunteers

M. A. Kolganova
E. E. Beketov
V. V. Pisarev
A. V. Ivanov
S. V. Vasiliev
I. E. Shokhin

Drug development & registration (2023) 12 (3): 240.

New Systemic Therapy Strategies for HER2-Positive Metastatic Breast Carcinoma

Maggie Banys-Paluchowski

Senologie - Zeitschrift für Mammadiagnostik und -therapie (2023) 20 (03): 257.

Trastuzumab biosimilars vs trastuzumab originator in the treatment of HER2-positive breast cancer: a systematic review and network meta-analysis

Tong Liu
Duo Liu
Yao Jin
Mei Dong

Immunopharmacology and Immunotoxicology (2022) 44 (6): 809.

Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?

Yujeong Kim
Hye-Young Kwon
Brian Godman
Evelien Moorkens
Steven Simoens
SeungJin Bae

Frontiers in Pharmacology (2020) 11

The role of teratogens in neural crest development

Santiago Cerrizuela
Guillermo A. Vega‐Lopez
Manuel J. Aybar

Birth Defects Research (2020) 112 (8): 584.

Ribociclib plus endokrine Therapie verbessert OS in der Prä-/Perimenopause

David Krug
Alexander Fabian
Jürgen Dunst
Dirk O. Bauerschlag

InFo Hämatologie + Onkologie (2020) 23 (5): 26.

Comparative efficacy and safety of trastuzumab biosimilars to the reference drug: a systematic review and meta-analysis of randomized clinical trials

Sarah Cargnin
Jae Il Shin
Armando A. Genazzani
Alessia Nottegar
Salvatore Terrazzino

Cancer Chemotherapy and Pharmacology (2020) 86 (5): 577.

Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab

Hans-Christian Kolberg
Marco Colleoni
Patricia Santi
Georgia Savva Demetriou
Miguel Angel Segui-Palmer
Yasuhiro Fujiwara
Sara A. Hurvitz
Vladimir Hanes

Targeted Oncology (2019) 14 (6): 647.